What are the anatomical variants of the middle meningeal artery (MMA) and their significance in middle meningeal artery embolisation for subdural hematoma (SDH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

MMA Anatomical Variants and Their Critical Significance in SDH Embolization

Understanding MMA anatomical variants is essential for safe and effective embolization, as frequent variations in branching patterns and dangerous anastomoses with the ophthalmic artery can lead to serious complications if not recognized pre-procedurally.

Key Anatomical Variants

Branching Pattern Variations (Extended Adachi Classification)

The traditional teaching that the anterior branch dominates (Type I) is only true in 41% of cases 1. More recent data shows:

  • Type IC is most common (19.82%) rather than the classic Type I pattern 2
  • Both anterior and posterior branches require targeting in the majority of patients to achieve adequate convexity devascularization 1
  • The posterior branch shows significant variability in its origin:
    • Proximal origin (Type A) occurs in 36% of cases, emerging at or immediately adjacent to the foramen spinosum 1
    • Distal segment origin is most common for the posterior branch 2

Clinical Implication: You cannot assume anterior branch dominance. Pre-procedural angiography must map both branches, and your embolization strategy should typically target both to prevent treatment failure.

Ophthalmic Artery Anastomoses - A Critical Safety Concern

This is where anatomical variants become dangerous:

  • Angiographic connections with the ophthalmic artery occur in 19% of cases 1
  • MMA originating directly from the ophthalmic artery occurs in 13.8% of CSDH patients - a strikingly high prevalence compared to only 0.7% in control populations (OR = 20) 3
  • This variant absolutely prohibits embolization due to risk of vision loss 3

Critical Pitfall: The extraordinarily high frequency of ophthalmic variants in CSDH patients (nearly 1 in 7) means you must perform meticulous selective catheterization and angiographic assessment before any embolization. Missing this variant can result in catastrophic visual complications.

Other Relevant Variants

  • Occipital artery anastomoses with posterior circulation exist and represent potential complications if not documented 4
  • MMA typically originates from the maxillary artery, but variants exist 2
  • Irregular, wispy distal MMA vasculature is commonly seen in CSDH, representing pathological neovasculature within the hematoma membrane 5

Pre-Procedural Angiographic Assessment Algorithm

Before embolization, you must:

  1. Perform selective catheterization of external carotid branches to confirm blood supply 4
  2. Perform superselective catheterization to reveal dangerous intracranial anastomoses 4
  3. Specifically evaluate for ophthalmic connections - look for:
    • Direct MMA origin from ophthalmic artery
    • Collateral pathways between MMA and orbital branches
  4. Map both anterior and posterior MMA branches - document their origins and territories
  5. Evaluate contralateral circulation if hematoma crosses midline 4

Clinical Significance for Treatment Strategy

When Variants Prohibit Embolization

Absolute contraindication: MMA arising from ophthalmic artery 3. This occurs in 13.8% of CSDH patients - you will encounter this frequently.

When Variants Modify Technique

  • Both branches typically require embolization given the 41% anterior dominance rate 1
  • Proximal posterior branch origin (36% of cases) may require different catheter positioning 1
  • The Adachi classification type itself does not significantly impact treatment results or fluoroscopy time 2, but recognition prevents incomplete treatment

Embolic Agent Considerations

While not strictly anatomical, the variants influence agent selection:

  • Particles (45-150 µm PVA) and liquid embolics (Onyx/EVOH) are both effective 6
  • Coil-only embolization shows 100% technical success with favorable outcomes 7
  • Distal penetration correlates with better resolution regardless of agent 7

Safety Profile When Anatomy is Respected

When anatomical variants are properly identified and dangerous anastomoses avoided:

  • No major procedural complications in recent large series 7
  • Recurrence reduction is significant (RR 0.47) 8
  • Adverse events comparable to usual care 8

The key message: MMA anatomy in CSDH patients is highly variable and frequently includes dangerous ophthalmic connections. Meticulous pre-procedural angiographic mapping is not optional - it is the difference between safe, effective treatment and potential catastrophic complications.

References

4
Guideline

head, neck, and brain tumor embolization guidelines.

Journal of Neurointerventional Surgery, 2012

5
Research

Middle meningeal artery embolization for chronic subdural hematoma: Endovascular technique and radiographic findings.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2018

Related Questions

In a 79-year-old patient with unilateral right leg swelling, a negative duplex ultrasound for deep venous thrombosis, and current furosemide (Lasix) 20 mg daily, what is the next step for the primary care physician?
What is the classification of diverticular disease?
How should electrolytes be monitored and replaced in a patient with fulminant Clostridioides difficile infection?
What is the appropriate evaluation and management of nocturnal enuresis in a 14-year-old with autism spectrum disorder and attention-deficit/hyperactivity disorder?
What is rechallenging in tuberculosis medications?
For a 72-year-old man with metastatic castration‑resistant prostate cancer involving bone, liver, and lung, PSMA‑low disease, and progression after two androgen receptor pathway inhibitors, docetaxel, cabazitaxel, and ^177Lu‑PSMA‑617, which statement about novel antibody‑drug conjugate strategies presented at ASCO 2026 is most accurate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.